<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665986</url>
  </required_header>
  <id_info>
    <org_study_id>NHP</org_study_id>
    <nct_id>NCT04665986</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer</brief_title>
  <official_title>A Study to Evaluate Navelbine in Combination With Trastuzumab Plus Pertuzumab in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer in Neoadjuvant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of&#xD;
      neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and&#xD;
      Pertuzumab given as neoadjuvant treatment in HER2 positive early-stage or locally advanced&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>Following surgery until Year 3</time_frame>
    <description>Disease-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DDFS</measure>
    <time_frame>Following surgery until Year 3</time_frame>
    <description>Distance Disease-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>NHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navelbine, Herceptin, Pertuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel, Herceptin, Pertuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navelbine</intervention_name>
    <description>Navelbine 25mg/m2 on day 1 and 8, every 3 weeks</description>
    <arm_group_label>NHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 90mg/m2 on day 1, every 3 weeks</description>
    <arm_group_label>THP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Female patients, 18 years ≤ age ≤ 80 years； Performance Status- Eastern Cooperative&#xD;
        Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer（early stage or&#xD;
        locally advanced） HER2 positive (HER2+++ by IHC or FISH+) Known hormone receptor status.&#xD;
        Cardiovascular: Baseline left ventricular ejection fraction (LVEF)≥55% measured by ECHO&#xD;
        Signed informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Metastatic disease (Stage IV) or inflammatory breast cancer Previous or current history of&#xD;
        malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of&#xD;
        the skin, Carcinoma in situ of the cervix.&#xD;
&#xD;
        Clinically relevant cardiovascular disease: Known history of uncontrolled or symptomatic&#xD;
        angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial&#xD;
        infarction, uncontrolled hypertension ≥180/110); Unable or unwilling to swallow tablets.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

